Synchronous fluorescence spectroscopy has been combined with immunoaffinity chromatography (IAC) and HPLC to detect polycyclic aromatic hydrocarbon (PAH)-DNA adducts and measure r-7,t4-8dihydroxy-t-9, 10-epoxy-7,8,9,10- 
Introduction
Polycyclic aromatic hydrocarbons (PAHs) form a major class of environmental pollutants; many of these compounds can be metabolized and activated to carcinogenic species that bind covalently with DNA (1). To measure genotoxic damage from PAHs, fluorescence techniques have been developed for the detection of DNA adducts, and r-7,t-8-dihydroxy-t-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE)-DNA adducts have been identified in human tissues (2) . Our strategy for detection and chemical characterization of adducts is based on combining the following preparative and analytical procedures: immunoaffinity chromatography is used to concentrate adducts ofa specific chemical class (PAHs); HPLC facilitates separation of DNA hydrolysis products; and synchronous fluorescence spectroscopy (SFS), second derivative synchronous fluorescence spectroscopy, and the generation of fluorescence excitation-emission matrices (FEEMs) provide chemically specific detection systems. Using this strategy (3, 4) 
Materials and Methods
Human lungs were collected at autopsy from the Department of Anatomic Pathology, University of Maryland. The tissues were stored at -70°C until DNA was extracted according to a previously described methodology (5) . Enzymic digests ofDNA were applied to immunoaffinity columns containing monoclonal antibodies directed against BPDE-modified guanosine (6) . The columns were then washed extensively with buffer, and bound materials were eluted with NaOH. Fractions eluted in NaOH were further hydrolyzed with HCI, and FEEMs were generated in the synchronous mode. Products of the acid hydrolysis were then separated by HPLC. Materials with retention times equal to those ofbenzo[a]pyrene-7,10/8,9-tetrahydrotetrol were further subjected to SFS using a wavelength difference (aX) of 34 nm. Serum was obtained from donors and assayed for the presence of cotinine using a radioimmunoassay (7) .
Results and Discussion
Synchronous fluorescence spectroscopy is highly specific for identification of aromatic nuclei because characteristic fluo- Figure 1 by a fluorescence emission peak at 379 nm (AX 34 nm); however, this signal does not dominate the matrix. In these studies, specificity is obtained through the chromatographic procedures and selection ofthe fluorescence parameters. Specificity is confirmed by the quality of the spectra observed. Fluorescent emissions from the pyrene fluorophore are not always obvious upon FEEM analysis of a complex mixture, as shown in Figure 2 . However, HPLC separation of the acid hydrolysate from which this FEEM was generated revealed a clear signal, specific for pyrene, when appropriate fractions were analyzed by SFS using AX 34 nm. Using both SFS AX 34 nm and second derivative spectroscopy to analyze HPLC eluates of the hydrolysis products of 1AC-concentrated adducts, the levels of BPDE-DNA adducts were determined for 25 lung samples. The zero-order and secondderivative synchronous fluorescence spectra (AX 34 nm) for materials isolated from human lung by IAC and HPLC are shown in Figure 3 . The presence of specific spectral signals (379 nm, emission X) and absence ofother nonspecific signals indicate that the isolate is pure. In previous studies the identity ofthis material as a pure isolate of the benzo[a]pyrene-7,10/8,9-tetrahydrotetrol was confirmed by GC-MS (4, 9) .
The levels of BPDE-DNA adducts detected in human peripheral lung samples (Table 1) were determined by comparison with a standard curve that was prepared from fluorescence peak heights generated by an authentic tetrol standard and radiolabeled positive control samples that were assayed together with human samples to account for efficiency of the preparative procedure (Table 1) . Tetrol recovery from 3H-BPDE-modified DNA samples ranged from 26 to 66% for the whole procedure. Assays were performed on coded sample sets that consisted of [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] human DNA samples and at least 2 positive and 2 negative control samples. Human peripheral lung DNA was assayed from a total of 25 individuals. There was sufficient tissue to independently extract DNA from 12 ofthe lung samples twice and 4 of them 3 times. Lung DNA from six individuals contained BPDE-DNA adduct levels between 23 and 1215 amole/ 
